Tag: Cancer Therapy
-
LncRNAs and MAPK Signaling in Breast Cancer: Interplay Driving Pathogenesis and Therapy Options
Introduction: The MAPK Landscape in Breast Cancer MAPK signaling is a cornerstone of cellular decision-making, translating external cues into outcomes such as proliferation, differentiation, migration, and survival. In breast cancer, three major MAPK branches—ERK, JNK, and p38—coordinate responses to growth factors, cytokines, and stress signals. While mutations in upstream components frequently hijack this network, noncoding…
-
New Strategy Targets EZH2 to Block TNBC Metastasis and Restore Chromosomal Stability
Breakthrough in Triple-Negative Breast Cancer: Targeting EZH2 to Halt Metastasis Triple-negative breast cancer (TNBC) remains one of the most aggressive and hard-to-treat forms of breast cancer. A new preclinical study from Weill Cornell Medicine proposes a surprising and hopeful strategy: inhibiting an enzyme called EZH2 to prevent cancer cells from disseminating to distant organs by…
-
R-nuucell joins EP PerMed to validate cancer therapy
R-nuucell selected by EP PerMed to validate a promising cancer therapy Portuguese biotechnology startup R-nuucell has been chosen to participate in the European Union’s EP PerMed program, a six-month initiative designed to advance precision medicine for cancer and other diseases. The Lisbon-based company was among eight startups selected for the program, which funds innovative projects…
-
R-nuucell chosen by EU EP PerMed to validate cancer therapy
R-nuucell among eight startups chosen for the EP PerMed six-month program The European program EP PerMed has selected eight innovative biotech ventures to advance personalized medicine, allocating six months of dedicated support and funding. The eight projects cover a range of cancer-related and genetic tools, rehabilitation, and tissue recovery solutions. Among them is the Portuguese…
-
R-nuucell Selected by EP PerMed to Validate Cancer Therapy
R-nuucell Joins EP PerMed to Validate a Novel Cancer Therapy A Portuguese biotech startup is taking a significant step forward in the fight against aggressive cancers. R-nuucell has been selected as one of eight European companies to participate in the EP PerMed program, a six-month initiative funded by the European Union aimed at validating promising…
-
China’s Spectacular Leap in Therapeutic Innovation: Breakthroughs in Cancer, Immunology, and Diabetes
China’s Breakthroughs in Therapeutic Innovation: Cancer, Immunology, and Diabetes In the past decade, China has transitioned from a manufacturing powerhouse to a global leader in therapeutic innovation. A convergence of ambitious public policy, expansive funding, and a fast-evolving regulatory framework has accelerated the development and approval of new therapies. The result is a chorus of…
-
PRMT5 Inhibition and Its Role in Inducing Ferroptosis in Renal Cell Carcinoma
Understanding Ferroptosis and Its Therapeutic Potential Ferroptosis is an emerging regulated cell death mechanism that has garnered significant attention for its potential in cancer therapy. This process is characterized by the rupture of the outer cell membrane and mitochondrial collapse, primarily driven by lipid peroxidation and iron accumulation. Recent studies have suggested that ferroptosis plays…